CONNECTA Therapeutics closed a €3.1 million financing led by Clave Capital to complete its Phase IIa trial of CTH120 in Fragile X syndrome.
- Amount
- $3.6M
- Announced
- 10 September 2026
- Lead
- Clave Capital
- Other investors
- Inveready, CDTI Innvierte, Prous Institute for Biomedical Research
- Use of funds
- Support completion of the ongoing Phase IIa trial of CTH120 in Fragile X syndrome, with topline data expected in mid-2027.
- Checked
- Announced by the company